Evidence map›Paper›PMID 31291846›Full record

ArticleLupus2019

Analysis of HLA-G expression in renal tissue in lupus nephritis: a pilot study.

V Foschi, D Bortolotti, A F Doyle, V Stratigou, L Stephens, P Trivedi, R Rinaldi, M Padovan, A Bortoluzzi, L Lightstone and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Immunogenetic Relationship ofInternational journal of general medicine · 2022
    Article
  2. HLA-G and the MHC Cusp Theory.Frontiers in immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

V Foschi1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.
D Bortolotti3 Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Italy.
A F Doyle2 Centre for Complement and Inflammation Research, Imperial College London, UK.
V Stratigou2 Centre for Complement and Inflammation Research, Imperial College London, UK.
L Stephens2 Centre for Complement and Inflammation Research, Imperial College London, UK.
P Trivedi4 Department of Pathology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
R Rinaldi5 Section of Pathology and Biomolecular Diagnostics, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Italy.
M Padovan1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.
A Bortoluzzi1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.
L Lightstone6 Section of Renal and Vascular Inflammation, Department of Medicine, Imperial College London, UK.
T D Cairns7 Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
M Botto2 Centre for Complement and Inflammation Research, Imperial College London, UK.
T H Cook2 Centre for Complement and Inflammation Research, Imperial College London, UK.
R Rizzo3 Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Italy.ORCID https://orcid.org/0000-0001-9507-9126
M Govoni1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.
M C Pickering2 Centre for Complement and Inflammation Research, Imperial College London, UK.
University of Ferrara · ITCentre for Inflammation Research · GBImperial College Healthcare NHS Trust · GB

Funding

Wellcome Trust 082291Wellcome Trust 098476
6 · The paper itself

Abstract

backgroundThe study aimed to investigate whether HLA-G antigen is expressed in the kidneys of patients affected by lupus nephritis (LN) and whether its detection in renal biopsies could be adopted as a marker of treatment response and prognosis.

methodsThirty renal biopsies from patients with LN were selected and analyzed through immunohistochemistry. Laboratory and clinical data were retrospectively collected at baseline, 6 and 12 months and at the latest clinical appointment. A number of patients (63.3%) were treated with rituximab (RTX) +/- methylprednisolone in the induction phase. The expression of HLA-G in glomeruli, tubules and infiltrating cells was examined and compared between lupus patients who achieved either complete or partial renal response and those who did not respond to treatment.

resultsHLA-G staining was observed in the glomeruli of 20 of 30 samples from patients with LN. The expression of the antigen was detected in podocytes, along glomerular capillary walls, on parietal glomerular epithelial cells and within the juxtaglomerular apparatus. Seventy per cent of patients whose glomeruli expressed HLA-G achieved partial or complete response at 6 months and 75% at the latest available follow up compared with 30% and 40%, respectively, of those who did not show any expression. The pattern of staining in tubules and infiltrating cells was highly variable precluding any clinical correlation.

conclusionThis study demonstrates that HLA-G is expressed in renal tissue in LN. Our retrospective data suggest that its expression could correlate with response to treatment.

Indexed as

AdultAnti-Inflammatory AgentsBiopsyFemaleFollow-Up StudiesHLA-G AntigensHumansImmunologic FactorsLupus NephritisMaleMethylprednisoloneMiddle AgedPilot ProjectsRetrospective StudiesRituximabTreatment OutcomeAnti-Inflammatory AgentsHLA-G AntigensImmunologic FactorsMethylprednisoloneRituximabHLA-Gimmunohistochemistrylupus nephritisrituximabSystemic lupus erythematosus

Identifiers

PMID31291846
PMCPMC7611013
OpenAlexW2957954184

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.